Pretreatment Detection, Surveillance, and Staging of Prostate Cancer

Prostate cancer is the second leading cause of cancer-related deaths in American men. Imaging tests and image-guided biopsies are used to help diagnose prostate cancer, for surveillance (watchful waiting) of low- and medium-risk prostate cancer, and for staging of medium- and high-risk prostate cancers.

For men with clinically suspected prostate cancer, with no prior biopsy or a negative transrectal ultrasound (TRUS)–guided biopsy, MRI-targeted biopsy, TRUS-guided biopsy, MRI pelvis without and with intravenous (IV) contrast, and MRI pelvis without IV contrast are usually appropriate.

For men with clinically established low-risk prostate cancer, MRI-targeted biopsy, TRUS-guided biopsy, MRI pelvis without and with contrast, and MRI pelvis without contrast are usually appropriate for surveillance.

For men with clinically established intermediate-risk prostate cancer, MRI-targeted biopsy, MRI abdomen and pelvis without and with contrast, MRI pelvis without and with contrast, CT abdomen and pelvis with contrast, PSMA PET/CT skull base to midthigh, CT chest abdomen pelvis with contrast, and fluciclovine PET/CT skull base to mid-thigh are usually appropriate for surveillance and staging.

For men with clinically established high-risk prostate cancer, MRI abdomen and pelvis without contrast, MRI pelvis without and with contrast, bone scan whole body, choline PET/CT skull base to mid-thigh, choline PET/MRI skull base to mid-thigh, CT abdomen and pelvis without contrast, fluciclovine PET/MRI skull base to mid-thigh, PSMA PET/CT skull base to mid-thigh, CT chest abdomen pelvis with IV contrast, fluciclovine PET/CT skull base to mid-thigh, and fluoride PET/CT whole body are usually appropriate for staging.

For more information, visit the Prostate Cancer page.

This page was reviewed on January 24, 2024

For more information about this and other radiology procedures, please visit Radiologyinfo.org